Free Trial
NASDAQ:AKYA

Akoya Biosciences Q4 2024 Earnings Report

Akoya Biosciences logo
$1.29 0.00 (0.00%)
As of 07/8/2025

Akoya Biosciences EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Akoya Biosciences Revenue Results

Actual Revenue
$21.34 million
Expected Revenue
$21.34 million
Beat/Miss
Beat by +$3.00 thousand
YoY Revenue Growth
N/A

Akoya Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Monday, March 17, 2025
Conference Call Time
1:30PM ET

Upcoming Earnings

Akoya Biosciences' Q2 2025 earnings is scheduled for Monday, August 4, 2025

Akoya Biosciences Earnings Headlines

AKYA Akoya Biosciences, Inc. - Seeking Alpha
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Akoya Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Akoya Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Akoya Biosciences and other key companies, straight to your email.

About Akoya Biosciences

Founded in 2016 and headquartered in Menlo Park, California, Akoya Biosciences (NASDAQ:AKYA) is a global leader in spatial biology solutions designed to accelerate the discovery and development of novel therapeutics. The company’s core mission is to provide researchers and pathologists with the tools necessary to visualize and quantify the spatial relationships of proteins, RNA, and other biomarkers in intact tissues, advancing our understanding of complex diseases such as cancer and autoimmune disorders.

Akoya’s product portfolio includes the CODEX (CO-Detection by indEXing) system, which enables highly multiplexed, single-cell imaging of formalin-fixed, paraffin-embedded (FFPE) and fresh-frozen tissue sections. The company also offers the Phenoptics line of immunofluorescence and chromogenic imaging platforms, accompanied by proprietary reagents and software analytics. These integrated solutions support both discovery research and translational studies, facilitating everything from early-stage biomarker identification to companion diagnostic development.

Serving a diverse clientele across academic institutions, pharmaceutical and biotechnology companies, and contract research organizations, Akoya maintains operations in North America, Europe, and the Asia-Pacific region. The company’s global reach is reinforced by strategic partnerships and distribution agreements, ensuring its technologies are accessible to a broad scientific community. Akoya’s instruments and assays have been utilized in hundreds of research publications, underscoring their impact on the life sciences field.

Akoya is led by an experienced management team with deep expertise in life sciences instrumentation and imaging technologies. The leadership group includes veterans from the biotech and pharmaceutical industries, supported by a board of directors committed to driving growth through innovation and customer-centric solutions. Under this guidance, Akoya continues to expand its product offerings and deepen its footprint in the burgeoning spatial biology market.

View Akoya Biosciences Profile

More Earnings Resources from MarketBeat